Clinical trials: Encephalitis Autoimmune
Multiple Sclerosis
TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants
The primary objective of the study is to estimate the incidence of progressive multifocal leukoencephalopathy (PML) and serious adverse events (SAEs) of other opportunistic infections (OIs) among all participants taking…
- Trial name
- NCT05236777
- Testing
- Natalizumab
- Where
- 15 sites in Czechia
- Volunteers
- 675 people
- Sponsor
- Biogen
Autoimmune Encephalitis (AE), Acute Disseminated Encephalomyelitis
OPM- MEG in Non-immune And iMmune-medIated Neurological Disease
Over the past 20 years, doctors have gotten much better at spotting and treating brain conditions caused by the immune system attacking the body. These include illnesses like autoimmune encephalitis, ADEM, and multiple sclerosis.
- Conditions
- Autoimmune Encephalitis (AE), Acute Disseminated Encephalomyelitis, Multiple Sclerosis
- Trial name
- O-MEG-A-MIND (NCT07689682)
- Testing
- OPM- Magnetoencephalography
- Where
- 2 sites in United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Aston University
Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder)
Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ART5803 following IVIG administration in healthy participants to investigate the potential interactions between ART5803 and IVIG
- Conditions
- Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder), Autoimmune Encephalitis
- Trial name
- NCT06753955
- Testing
- ART5803, Intravenous immunoglobulin (IVIG)
- Where
- Australia
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Arialys Therapeutics
Paraneoplastic Neurological Syndrome, Autoimmune Encephalitis
Diagnostic Performance of a Commercial Assay for the Detection of Neuronal Antibodies
Detection of autoantibodies targeting neuronal surface or intracellular antigens is a keystone for the diagnosis and the treatment of auto-immune encephalitis and paraneoplastic neurological syndromes.
- Trial name
- IFINEURO (NCT05783947)
- Testing
- Indirect immunofluorescence assay on tissue slides and cell-based assays with CSF and/or sera
- Where
- 2 sites in France
- Volunteers
- 34 people
- Sponsor
- Hospices Civils de Lyon
Autoimmune Encephalitis
Clinical Characteristics of Patients With Anti-Collapsin Response Mediator Protein 2 Antibodies in Encephalitis or Encephalomyelitis
Autoimmune encephalitis (AE) is an important autoimmune neurological disease, and its clinical manifestations, treatment and prognosis are closely related to the type of pathogenic antibodies.
- Trial name
- NCT07036042
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Systemic Lupus Erthematosus (SLE), Progressive Multiple Sclerosis (PMS)
A Basket Study of CTA313 in Participants With Active Autoimmune Diseases
The goal of the ALLNEW clinical trial is to learn if CTA313 UCART is safe and effective for patients with immune mediated disorders.
- Conditions
- Systemic Lupus Erthematosus (SLE), Progressive Multiple Sclerosis (PMS), Autoimmune Encephalitis
- Trial name
- ALLNEW (NCT07783269)
- Testing
- CTA313 UCAR T Cell Infusion
- Volunteers
- 81 people
- Sponsor
- Imviva Bio
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis
The main objective is to explore the efficacy and safety of Telitacicept in the treatment of refractory/recurrent anti-NMDAR and anti-LGI1 encephalitis.
- Trial name
- NCT06510283
- Testing
- Taitacept
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing Tongren Hospital
Multiple Sclerosis
Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis
Under the escalation treatment strategy when a patient displays breakthrough disease parameters under first line therapy, MS physicians are allowed by the EMEA to switch for Natalizumab (NTZ) or fingolimod (FGL).
- Trial name
- BEST-MS (NCT01981161)
- Testing
- biological samples and clinical data
- Where
- 12 sites in France, Germany and 1 more
- Volunteers
- 307 people
- Sponsor
- University Hospital, Toulouse
Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy
Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia
This study will evaluate the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by John Cunningham virus (JCV), among people with multiple sclerosis who have been treated with ozanimod.
- Trial name
- NCT07732907
- Testing
- Ozanimod
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Down Syndrome, Regression
Therapies for Down Syndrome Regression Disorder
Individuals with Down syndrome (DS) have an increased risk of numerous co-occurring conditions, including the neuropsychiatric condition known as Down Syndrome Regression Disorder (DSRD).
- Trial name
- NCT05662228
- Testing
- Lorazepam, Intravenous immunoglobulin (IVIG), Tofacitinib
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- University of Colorado, Denver
Autoimmune Encephalitis, Anti-NMDAR Encephalitis
Clinical Evaluation of a Novel DAB Chromogenic Tissue-Based Assay for Detecting Anti-GABABR Antibodies
This multicenter, blinded, cross-sectional study aims to evaluate the clinical performance of a novel DAB chromogenic tissue-based assay (TBA) for detecting anti-GABAB receptor (anti-GABABR) antibodies.
- Conditions
- Autoimmune Encephalitis, Anti-NMDAR Encephalitis, Anti-GABABR Encephalitis
- Trial name
- GREAT (NCT07858175)
- Where
- 5 sites in China
- Volunteers
- 300 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Systemic Lupus Erythematosus (SLE), Lupus Nephritis
Lupus Landmark Study: A Prospective Registry and Biorepository
The purpose of the registry and biorepository is to provide a mechanism to store clinical data, linked biospecimens and molecular data to support the conduct of future research on Systemic Lupus Erythematosus (SLE), including…
- Conditions
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Neuropsychiatric Systemic Lupus Erythematosus
- Trial name
- NCT05934149
- Where
- 25 sites in United States, Canada
- Volunteers
- 3,500 people
- Sponsor
- Lupus Research Alliance
Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder
Biomarkers in Autoimmune Disease of Nervous System
Neurological autoimmune diseases are a group of disorders characterized by the abnormal immune response attacking the nervous system, including the brain, spinal cord and peripheral nerves.
- Conditions
- Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder, Multiple Sclerosis, Guillain-Barre Syndrome
- Trial name
- NCT06502015
- Testing
- biomaker levels
- Where
- China
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Anti-NMDA Receptor Encephalitis
Transcranial Direct Current Stimulation on Cortical Plasticity in Patients With Anti-NMDA Receptor Encephalitis
Patients suffering from anti-NMDA receptor encephalitis show impaired NMDA-receptor dependent neuronal transmission. Furthermore, they often have cognitive deficits of different magnitude.
- Trial name
- NCT01865578
- Testing
- tDCS
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Epilepsy, Encephalitis Autoimmune
Neural Autoantibody Prevalence in New-onset Focal Seizures of Unknown Etiology
Seizure is one of the most common symptoms in autoimmune encephalitis with neuronal surface-mediated antibodies. Interestingly, some patients may exhibit new-onset seizures as the initial manifestation without fulminant sign of…
- Trial name
- NCT06388161
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shen Chun-Hong
Autoimmune Encephalopathy
Effect of Vigabatrin in Refractory Autoimmune Encephalitis Patients
Investigation of efficacy of vigabatrin in refractory autoimmune encephalitis patients
- Trial name
- NCT03003143
- Testing
- Vigabatrin 500 MG
- Where
- South Korea
- Sponsor
- Seoul National University Hospital
Autoimmune Encephalitis (AE)
Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis?
This study aims to evaluate the effectiveness of [18F]-DPA-714 PET imaging in detecting neuroimmune activity in patients with autoimmune encephalitis (AE).
- Trial name
- EAI-714 (NCT07488117)
- Testing
- TEP with radioligand EAI 714
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Autoimmune Encephalitis, Encephalitis
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and…
- Trial name
- ExTINGUISH (NCT04372615)
- Testing
- Inebilizumab
- Where
- 39 sites in United States, Netherlands and 1 more
- Volunteers
- 116 people
- Sponsor
- University of Utah
Anti-NMDA Receptor Encephalitis
Antibody-mediated NMDA Receptor Encephalitis: Symptoms, Biomarkers, and Mechanisms of the Prolonged Recovery Stage
The encephalitis mediated by antibodies against the NMDA receptor (NMDARe) predominantly affects young adults and children resulting in severe neurologic and psychiatric deficits.
- Trial name
- AMENDS (NCT06183788)
- Testing
- Remote cognitive rehabilitation program
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Autoimmune Encephalitis
Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:
The purpose of this study is to evaluate the safety and efficacy of IGIV 10% in patients with autoimmune encephalitis
- Trial name
- NCT04175522
- Testing
- Immunoglobulin G
- Where
- South Korea
- Volunteers
- 23 people
- Sponsor
- Green Cross Corporation